BioCentury | Dec 19, 2020
Product Development

Asymptomatic COVID-19 testing reaches inflection point

With the pandemic raging, regulators are breaking down the distinction between symptomatic and asymptomatic COVID-19 testing, and opening the door to individual self-screening. Communications from FDA...
BioCentury | Dec 11, 2020
Product Development

Strides forward for COVID-19 screening as FDA authorizes first consumer home collection kit, with OTC rapid test in the pipeline

The piecemeal move toward more broadly accessible COVID-19 testing took two steps forward, with the first FDA authorization for a direct-to-consumer home sample collection kit, and an EUA application for an over-the-counter rapid antigen test....
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

CBC portfolio company Nuance closes $181M series DNuance Biotech raised $181 million in a series D round led by RTW Investments and GT Fund with participation by existing investors CBC Group, Matrix Partners China and...
BioCentury | Nov 18, 2020
Product Development

Annual BayHelix awards highlight China’s growing life sciences sector; HKEX’s Li, Zai’s Du, Innovent among winners

In an award ceremony recognizing eight achievements in the life sciences in China this year, BayHelix highlighted the rapid growth of financing and deals by China’s biopharma companies. Innovent took home the Company of the Year...
BioCentury | Nov 3, 2020
Finance

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

JW makes public debut on Hong Kong exchangeIn its first day of trading Tuesday, JW Therapeutics Co. Ltd. (HKEX:2126) fell HK$1.80 to HK$22 after raising HK$2.3 billion ($300 million) in an IPO. Bristol Myers Squibb...
BioCentury | Oct 7, 2020
Product Development

Oct. 6 Quick Takes: BARDA whistleblower quits NIH; plus COVID-19 updates from Vir-GSK, BioNTech, Pfizer, $115M B round for Talaris and more

Former BARDA Director Bright leaving NIH Rick Bright, the former director of the Biomedical Advanced Research and Development Authority and HHS deputy assistant secretary for preparedness and response, has resigned from NIH, according to a...
BioCentury | Oct 6, 2020
Deals

Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more

BridgeBio reacquiring Eidos spinoutFour years after spinning out Eidos Therapeutics Inc. (NASDAQ:EIDX), BridgeBio Pharma Inc. (NASDAQ:BBIO) will acquire the 36.3% of that company it does not already own. Eidos’ lead program acoramidis (AG-10) is in...
BioCentury | Oct 2, 2020
Distillery Therapeutics

IL-12B monomers to treat multiple sclerosis, rheumatoid arthritis

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis (MS); rheumatoid arthritis (RA) Monomers of IL-12B, which can dimerize with itself, IL-12A or IL23P19, could treat autoimmune disorders including MS and RA. Relapsing-remitting MS patients had higher...
BioCentury | Jul 29, 2020
Distillery Therapeutics

CAPN2 inhibition for concussion-associated neuropathy and behavioral changes

DISEASE CATEGORY: Neurology INDICATION: Neurology Inhibiting the calcium-dependent protease CAPN2 could treat neuropathy and behavioral changes caused by repeated concussions. In a mouse model of traumatic brain injury mediated by controlled cortical impact, excitatory neuron-specific...
BioCentury | Jul 10, 2020
Tools & Techniques

Precise base editing of mitochondrial DNA

David Liu and colleagues at the Broad Institute and University of Washington have achieved single-base editing of mitochondrial DNA for the first time, overcoming a limitation of CRISPR-based technologies and opening up new avenues for...
Items per page:
1 - 10 of 744
BioCentury | Dec 19, 2020
Product Development

Asymptomatic COVID-19 testing reaches inflection point

With the pandemic raging, regulators are breaking down the distinction between symptomatic and asymptomatic COVID-19 testing, and opening the door to individual self-screening. Communications from FDA...
BioCentury | Dec 11, 2020
Product Development

Strides forward for COVID-19 screening as FDA authorizes first consumer home collection kit, with OTC rapid test in the pipeline

The piecemeal move toward more broadly accessible COVID-19 testing took two steps forward, with the first FDA authorization for a direct-to-consumer home sample collection kit, and an EUA application for an over-the-counter rapid antigen test....
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

CBC portfolio company Nuance closes $181M series DNuance Biotech raised $181 million in a series D round led by RTW Investments and GT Fund with participation by existing investors CBC Group, Matrix Partners China and...
BioCentury | Nov 18, 2020
Product Development

Annual BayHelix awards highlight China’s growing life sciences sector; HKEX’s Li, Zai’s Du, Innovent among winners

In an award ceremony recognizing eight achievements in the life sciences in China this year, BayHelix highlighted the rapid growth of financing and deals by China’s biopharma companies. Innovent took home the Company of the Year...
BioCentury | Nov 3, 2020
Finance

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

JW makes public debut on Hong Kong exchangeIn its first day of trading Tuesday, JW Therapeutics Co. Ltd. (HKEX:2126) fell HK$1.80 to HK$22 after raising HK$2.3 billion ($300 million) in an IPO. Bristol Myers Squibb...
BioCentury | Oct 7, 2020
Product Development

Oct. 6 Quick Takes: BARDA whistleblower quits NIH; plus COVID-19 updates from Vir-GSK, BioNTech, Pfizer, $115M B round for Talaris and more

Former BARDA Director Bright leaving NIH Rick Bright, the former director of the Biomedical Advanced Research and Development Authority and HHS deputy assistant secretary for preparedness and response, has resigned from NIH, according to a...
BioCentury | Oct 6, 2020
Deals

Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more

BridgeBio reacquiring Eidos spinoutFour years after spinning out Eidos Therapeutics Inc. (NASDAQ:EIDX), BridgeBio Pharma Inc. (NASDAQ:BBIO) will acquire the 36.3% of that company it does not already own. Eidos’ lead program acoramidis (AG-10) is in...
BioCentury | Oct 2, 2020
Distillery Therapeutics

IL-12B monomers to treat multiple sclerosis, rheumatoid arthritis

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis (MS); rheumatoid arthritis (RA) Monomers of IL-12B, which can dimerize with itself, IL-12A or IL23P19, could treat autoimmune disorders including MS and RA. Relapsing-remitting MS patients had higher...
BioCentury | Jul 29, 2020
Distillery Therapeutics

CAPN2 inhibition for concussion-associated neuropathy and behavioral changes

DISEASE CATEGORY: Neurology INDICATION: Neurology Inhibiting the calcium-dependent protease CAPN2 could treat neuropathy and behavioral changes caused by repeated concussions. In a mouse model of traumatic brain injury mediated by controlled cortical impact, excitatory neuron-specific...
BioCentury | Jul 10, 2020
Tools & Techniques

Precise base editing of mitochondrial DNA

David Liu and colleagues at the Broad Institute and University of Washington have achieved single-base editing of mitochondrial DNA for the first time, overcoming a limitation of CRISPR-based technologies and opening up new avenues for...
Items per page:
1 - 10 of 744